BIOLOGICAL
SAL001
administrated once by subcutaneous injection
Bioequivalence Study of SAL001 and FORSTEO in Healthy Chinese Adults
Status
Completed
Phase
Phase 1
Enrollment
64
Locations
1
Results
Not posted
Publications
0
Study summary
What the protocol is testing.
This is a single-center, randomized, open label, single-dose, the original drug controlled, crossover design, two sequence, two periods, Phase Ⅰclinical study. 64 qualified subjects will be randomly assigned to two administration sequences (sequence A and sequence B) at the ratio of 1∶1, with 32 subjects in each sequence. Each period will be given subcutaneous injection once, and the washout period will be 72 hours, and each subject will be given subcutaneous injection twice. Sequence A: the test drug (SAL001) is injected in the first period, and the reference drug (FORSTEO) is injected in the second period. Sequence B: the reference drug (FORSTEO) is injected in the first period, and the test drug (SAL001) is injected in the second period. If the geometric mean ratio (GMR) 90% confidence interval of the major pharmacokinetic indexes (AUC0-t, Cmax) for SAL001 and FORSTEO is between 80.00% and 125.00%, the two drugs are considered to be bioequivalent.
Interventions
Treatment arms and agents.
BIOLOGICAL
FORSTEO
administrated once by subcutaneous injection
Timeline
From registration to results.
First posted
Feb 10, 2021
Study start
Aug 19, 2020
Primary completion
Oct 30, 2020
Study completion
Nov 11, 2020
Results posted
Not reported
Registry updated
Feb 10, 2021
Outcomes
What the study measures.
Primary outcomes
PK parameters: area under the plasma concentration time curve from-time zero to time t (AUC0-t)
Time frame · Within 60 minutes before administration, and 5, 10, 15, 20, 30, 40, 50, 60, 75, 90, 120, 150, 180, 210, 240, and 300 minutes after administration of Day 1 and Day 4
Central lab will be used to detect the plasma concentration of drugs.
PK parameters: peak plasma concentration (Cmax)
Time frame · Within 60 minutes before administration, and 5, 10, 15, 20, 30, 40, 50, 60, 75, 90, 120, 150, 180, 210, 240, and 300 minutes after administration of Day 1 and Day 4
Central lab will be used to detect the plasma concentration of drugs.
Secondary outcomes
PK parameters: area under the plasma concentration time curve from time zero to time infinity (AUC0-∞)
Time frame · Within 60 minutes before administration, and 5, 10, 15, 20, 30, 40, 50, 60, 75, 90, 120, 150, 180, 210, 240, and 300 minutes after administration of Day 1 and Day 4
Central lab will be used to detect the plasma concentration of drugs.
PK parameters: time to reach peak drug concentration (Tmax)
Time frame · Within 60 minutes before administration, and 5, 10, 15, 20, 30, 40, 50, 60, 75, 90, 120, 150, 180, 210, 240, and 300 minutes after administration of Day 1 and Day 4
Central lab will be used to detect the plasma concentration of drugs.
PK parameters: half-life (t1/2)
Time frame · Within 60 minutes before administration, and 5, 10, 15, 20, 30, 40, 50, 60, 75, 90, 120, 150, 180, 210, 240, and 300 minutes after administration of Day 1 and Day 4
Central lab will be used to detect the plasma concentration of drugs.
PK parameters: AUC extrapolated from Tmax to infinity in percentage of the total AUC (AUC%extrap)
Time frame · Within 60 minutes before administration, and 5, 10, 15, 20, 30, 40, 50, 60, 75, 90, 120, 150, 180, 210, 240, and 300 minutes after administration of Day 1 and Day 4
Central lab will be used to detect the plasma concentration of drugs.
PK parameters: time to last measurable concentration (Tlast)
Time frame · Within 60 minutes before administration, and 5, 10, 15, 20, 30, 40, 50, 60, 75, 90, 120, 150, 180, 210, 240, and 300 minutes after administration of Day 1 and Day 4
Central lab will be used to detect the plasma concentration of drugs.
PK parameters: terminal elimination rate constant (λz)
Time frame · Within 60 minutes before administration, and 5, 10, 15, 20, 30, 40, 50, 60, 75, 90, 120, 150, 180, 210, 240, and 300 minutes after administration of Day 1 and Day 4
Central lab will be used to detect the plasma concentration of drugs.
PK parameters: apparent total clearance (CL/F)
Time frame · Within 60 minutes before administration, and 5, 10, 15, 20, 30, 40, 50, 60, 75, 90, 120, 150, 180, 210, 240, and 300 minutes after administration of Day 1 and Day 4
Central lab will be used to detect the plasma concentration of drugs.
PK parameters: apparent distribution volume (Vz/F)
Time frame · Within 60 minutes before administration, and 5, 10, 15, 20, 30, 40, 50, 60, 75, 90, 120, 150, 180, 210, 240, and 300 minutes after administration of Day 1 and Day 4
Central lab will be used to detect the plasma concentration of drugs.
PK parameters: mean residence time from time zero to t (MRT0-t)
Time frame · Within 60 minutes before administration, and 5, 10, 15, 20, 30, 40, 50, 60, 75, 90, 120, 150, 180, 210, 240, and 300 minutes after administration of Day 1 and Day 4
Central lab will be used to detect the plasma concentration of drugs.
PK parameters: mean residence time from time zero to infinity (MRT0-∞)
Time frame · Within 60 minutes before administration, and 5, 10, 15, 20, 30, 40, 50, 60, 75, 90, 120, 150, 180, 210, 240, and 300 minutes after administration of Day 1 and Day 4
Central lab will be used to detect the plasma concentration of drugs.
Eligibility
Who can take part.
- Minimum age
- 20 Years
- Maximum age
- 50 Years
- Sex
- ALL
- Healthy volunteers
- Yes
Inclusion Criteria: 1. Those who volunteer to participate in the trial and sign the informed consent form. 2. Healthy Chinese male or female adults, the number of single sex volunteers is no less than 1/3, aged 20 to 50 years old (including the boundary value). 3. Males weighted ≥50kg, females weighted ≥45kg, body mass index (BMI) between 19-25 kg/m\^2 (including boundary value), BMI= weight (kg)/height\^2 (m\^2). Exclusion Criteria: 1. The existence of clinically significant diseases of heart, liver, lung, kidney, digestive tract, endocrine, metabolic and hematological systems. 2. history of parathyroid disease, or abnormal PTH with clinically significance judged by investigators. 3. Physical examination, laboratory examination, electrocardiogram (ECG), chest radiograph, abdominal ultrasound san(digestive system, urinary system), vital signs, etc., indicate that the subject has clinically significant abnormalities judged by the investigator. 4. Serum total calcium \> upper limit of normal according to the normal range of the center, or previous hypercalcemia. 5. Hyperuricemia, or a previous history of gout, or abnormal blood uric acid with clinically significance judged by investigators at the time of screening. 6. Those with active urolithiasis. 7. Those who had received anti-osteoporosis agents (such as bisphosphonates, calcitonin, estrogen, selective estrogen receptor modulator, parathyroid hormone and its analogues, strontium salts, active vitamin D and its analogues, vitamin K2, etc.) within 6 months before the first administration of the trial. 8. Those who had received oral or intravenous administration of glucocorticoids 3 months before the first administration of the trial. 9. Those who had taken any drug within 14 days before the first administration of the trial. 10. Allergies, such as allergic to two or more kinds of drugs or food; or known allergic to this drug components. 11. Alcoholism within 1 year before screening (drinking more than 3 times a day or more than 7 times a week, drinking 1 time =150mL red wine, or 360mL beer, or 50mL white wine), or a positive alcohol breath test. 12. A history of drug abuse within 1 year before screening, or a positive urine test for drugs at screening. 13. Those who were smoking more than 5 cigarettes a day within 3 months before screening. 14. Those who had participated in any other clinical trial within 3 months before the first administration of the trial. 15. Those who had blood donation or blood loss ≥400mL within 3 months before the first administration of the trial. 16. Those who do not agree to avoid the use of tobacco, alcohol or caffeinated beverages within 24 hours before the administration and during the trial, or do not agree to avoid strenuous exercise, or do not agree to avoid other factors affecting the absorption, distribution, metabolism and excretion of the drug. 17. Women who are pregnant or lactating, or who are positive for serum HCG, or who cannot/do not follow the instructions of investigators to take contraceptive measures approved by investigators during the study period. 18. Those who intend to give birth within 1 year. 19. Those with positive results of HBV surface antigen, or hepatitis C virus antibody positive, or Treponema pallidum antibody positive, or human immunodeficiency virus antibody positive. 20. Those with positive results of novel coronavirus nucleic acid test. 21. Those who are considered to be unsuitable for participation in this clinical study by investigators.
Study locations
1 registered sites.
China. Showing up to 24 locations stored in the fast local snapshot.
The Fifth Affiliated Hospital of Guangzhou Medical University
Guangzhou, Guangdong, China
Publications
Results and literature.
No PMID-linked publications were present in this registry snapshot.
Related trials
More studies on Teriparatide.
NCT IDStudyPhase / statusEnrollmentUpdated
Sequential Therapies After Osteoanabolic Treatment
424 General Military Hospital · Osteoporosis, Postmenopausal
Not applicable
Recruiting
150
2026-07
A Study of B-3E07 and Forsteo® in Healthy Adult Female Participants
Syneos Health · Healthy Volunteers
Phase 1
Recruiting
48
2026-07
Treatment of Osteogenesis Imperfecta With Parathyroid Hormone and Zoledronic Acid
University of Edinburgh · Osteogenesis Imperfecta
Phase 4
Completed
350
2026-06
Teriparatide (Forsteo) Treatment in Postmenopausal Women: Mechanism of Action
Sheffield Teaching Hospitals NHS Foundation Trust · Osteoporosis
Phase 4
Completed
19
2026-05
Preoperative Teriparatide Use on Insertional Torque of Pedicle Screws for Lumbar Fusion Surgery
The University of Hong Kong · Osteoporosis · Fusion of Spine, Lumbar Region
Not applicable
Active, not recruiting
192
2026-05
Novel Precision Medicine Approach to Treatment of Osteoporosis Based on Bone Turnover
Madhumathi Rao · Age-Related Osteoporosis
Phase 4
Active, not recruiting
60
2026-05
A Phase II Clinical Trial of the Safety and Efficacy of SAL056 at Different Doses and Dosing Regimens
Shenzhen Salubris Pharmaceuticals Co., Ltd. · Postmenopausal Women With Osteoporosis
Phase 2
Recruiting
200
2026-05
Effects of Teriparatide (PTH) on Bone in Men and Women With Osteoporosis
University Health Network, Toronto · Osteoporosis
Not applicable
Active, not recruiting
100
2026-05
Related PeptideStat pages
Put the record in context.
Research pages describe evidence. Vendor pages, where available, describe independently tracked research-product listings and are not clinical recommendations.